Gilead, MicroDose Therapeutx ink licensing pact
MicroDose intends to submit the investigational new drug (IND) reactivation with the US Food and Drug Administration and to begin MDT-637Phase I study this year. As per the
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Study of V-101 is a randomized, multi-centered, double-blinded, vehicle-controlled, Phase II clinical trial designed to evaluate the dose-response relationship of two concentrations of V-101 cream vs. vehicle (placebo).